Interleukin-1 receptor-associated kinase 1 · SINGLE PROTEIN · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-13Interleukin-1 receptor-associated kinase 1 shows approved-linked disease relevance led by polycythemia vera. 1 more disease program remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P51617. Start with polycythemia vera, then reuse UniProt P51617 as the stable protein anchor across project notes and exports.
Start with polycythemia vera, then reuse UniProt P51617 as the stable protein anchor across project notes and exports.
Interleukin-1 receptor-associated kinase 1 shows approved-linked disease relevance led by polycythemia vera. 1 more disease program remain visible in the same review block. 1 linked drug remains visible in the same block.
Start review with polycythemia vera because it currently carries approved-linked support. Linked drugs include PACRITINIB CITRATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyInterleukin-1 receptor-associated kinase 1
Review this target as Interleukin-1 receptor-associated kinase 1, mapped to UniProt P51617. Sequence length is 712 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Interleukin-1 receptor-associated kinase 1 as ChEMBL target CHEMBL3357, mapped to UniProt P51617. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Interleukin-1 receptor-associated kinase 1 is the right protein anchor across sources, using UniProt P51617 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why polycythemia vera is currently framed as approved-linked support. It currently carries 1 linked drug in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Interleukin-1 receptor-associated kinase 1 |
| Target Type | SINGLE PROTEIN |
| Organism | Homo sapiens |
| UniProt | P51617 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Interleukin-1 receptor-associated kinase 1 |
| UniProt Accession | P51617 |
| Component Type | Protein |
| Sequence Length | 712 aa |
Interleukin-1 receptor-associated kinase 1
Review this target as Interleukin-1 receptor-associated kinase 1, mapped to UniProt P51617. Sequence length is 712 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Interleukin-1 receptor-associated kinase 1 shows approved-linked disease relevance led by polycythemia vera. 1 more disease program remain visible in the same review block.
Start review with polycythemia vera because it currently carries approved-linked support. Linked drugs include PACRITINIB CITRATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL5283628 | 8.7 | IC50 | 2.0 | Preclinical |
| CHEMBL5927784 | 8.54 | Kd | 2.9 | Preclinical |
| CHEMBL6002371 | 8.46 | Kd | 3.5 | Preclinical |
| CHEMBL5949720 | 8.27 | IC50 | 5.34 | Preclinical |
| CHEMBL2172315 | 8.25 | Kd | 5.6 | Preclinical |
| CHEMBL2172308 | 8.24 | Kd | 5.7 | Preclinical |
| CHEMBL603469 | 8.21 | Kd | 6.1 | Clinical |
| CHEMBL5907315 | 8.15 | IC50 | 7.0 | Preclinical |
| CHEMBL4568087 | 8.05 | IC50 | 9.0 | Preclinical |
| CHEMBL4782804 | 8.05 | IC50 | 9.0 | Preclinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| single protein format | 251 | 358 | 6.2 |
| assay format | 39 | 18 | 6.7 |
| cell-based format | 36 | 10 | 7.2 |
| subcellular format | 17 | 16 | 5.9 |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 1 | 10 | 6.3 |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| assay format | 1 | 226 | 5.9 |